{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:19:47Z","timestamp":1794356387189,"version":"4.9.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["DP150029"],"award-info":[{"award-number":["DP150029"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41591-025-03650-6","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:02:17Z","timestamp":1744174937000},"page":"2365-2374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-4087","authenticated-orcid":false,"given":"Martin","family":"Wermke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejka M.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-523X","authenticated-orcid":false,"given":"Tobias A. W.","family":"Holderried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-4151","authenticated-orcid":false,"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9546","authenticated-orcid":false,"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-2437","authenticated-orcid":false,"given":"Winfried","family":"Alsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Wetzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Backert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-8577","authenticated-orcid":false,"given":"Jens","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Gulde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-0800","authenticated-orcid":false,"given":"Silvana","family":"Hengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-8174","authenticated-orcid":false,"given":"Norbert","family":"Hilf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad B.","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hukelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delfi","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alper","family":"Kursunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mayer-Mokler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Mendrzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Satelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Letizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1614-2647","authenticated-orcid":false,"given":"Hans-Georg","family":"Rammensee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Singh-Jasuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Weinschenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason J.","family":"Luke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-8760","authenticated-orcid":false,"given":"Cedrik M.","family":"Britten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"3650_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","volume":"41","author":"SM Norberg","year":"2023","unstructured":"Norberg, S. M. & Hinrichs, C. S. Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell 41, 58\u201369 (2023).","journal-title":"Cancer Cell"},{"key":"3650_CR2","doi-asserted-by":"crossref","unstructured":"Leko, V. & Rosenberg, S. A. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell 38, 454\u2013472 (2020).","DOI":"10.1016\/j.ccell.2020.07.013"},{"key":"3650_CR3","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","volume":"22","author":"CA Klebanoff","year":"2023","unstructured":"Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A. & Ribas, A. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nat. Rev. Drug Discov. 22, 996\u20131017 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3650_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"3650_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00262-017-2073-0","volume":"67","author":"T Moore","year":"2018","unstructured":"Moore, T. et al. Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunol. Immunother. 67, 311\u2013325 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"3650_CR6","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"3650_CR7","doi-asserted-by":"crossref","unstructured":"Hong, D. S. et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 29, 104\u2013114 (2023).","DOI":"10.1038\/s41591-022-02128-z"},{"key":"3650_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419\u2013425 (2021).","journal-title":"Nat. Med."},{"key":"3650_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma. Cancer Discov. 8, 944\u2013957 (2018).","journal-title":"Cancer Discov."},{"key":"3650_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda, H. et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6, 199\u2013208 (1997).","journal-title":"Immunity"},{"key":"3650_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","volume":"46","author":"M Kaczorowski","year":"2022","unstructured":"Kaczorowski, M. et al. PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 46, 1467\u20131476 (2022).","journal-title":"Am. J. Surg. Pathol."},{"key":"3650_CR12","doi-asserted-by":"crossref","unstructured":"Lezcano, C., Jungbluth, A. A., Nehal, K. S., Hollmann, T. J. & Busam, K. J. PRAME expression in melanocytic tumors. Am. J. Surg. Pathol. 42, 1456\u20131465 (2018).","DOI":"10.1097\/PAS.0000000000001134"},{"key":"3650_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1159\/000487353","volume":"45","author":"H Zhu","year":"2018","unstructured":"Zhu, H. et al. Downregulation of PRAME suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of p53 mediated pathway. Cell. Physiol. Biochem. 45, 1121\u20131135 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"3650_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1084\/jem.193.1.73","volume":"193","author":"JH Kessler","year":"2001","unstructured":"Kessler, J. H. et al. Efficient identification of novel HLA-A*0201\u2013presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.J. Exp. Med. 193, 73\u201388 (2001).","journal-title":"J. Exp. Med."},{"key":"3650_CR15","first-page":"5818","volume":"62","author":"T Weinschenk","year":"2002","unstructured":"Weinschenk, T. et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62, 5818\u20135827 (2002).","journal-title":"Cancer Res."},{"key":"3650_CR16","doi-asserted-by":"publisher","first-page":"e1700284","DOI":"10.1002\/pmic.201700284","volume":"18","author":"J Fritsche","year":"2018","unstructured":"Fritsche, J. et al. Translating immunopeptidomics to immunotherapy-decision-making for patient and personalized target selection. Proteomics 18, e1700284 (2018).","journal-title":"Proteomics"},{"key":"3650_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3650_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32491-x","volume":"13","author":"A Gyurdieva","year":"2022","unstructured":"Gyurdieva, A. et al. Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. Nat. Commun. 13, 5296 (2022).","journal-title":"Nat. Commun."},{"key":"3650_CR19","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/cancers13153912","volume":"13","author":"W Lei","year":"2021","unstructured":"Lei, W. et al. Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis. Cancers (Basel) 13, 3912 (2021).","journal-title":"Cancers (Basel)"},{"key":"3650_CR20","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","volume":"29","author":"A Kawai","year":"2023","unstructured":"Kawai, A. et al. Safety and efficacy of NY-ESO-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: a phase I\/II clinical trial. Clin. Cancer Res. 29, 5069\u20135078 (2023).","journal-title":"Clin. Cancer Res."},{"key":"3650_CR21","doi-asserted-by":"publisher","unstructured":"D\u2019Angelo, S. P. et al. Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid\/round cell liposarcoma (MRCLS). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.11500 (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.11500"},{"key":"3650_CR22","doi-asserted-by":"crossref","unstructured":"Hong, D. S. et al. Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors. Ann. Oncol. 33, S879\u2013S880 (2022).","DOI":"10.1016\/j.annonc.2022.07.861"},{"key":"3650_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.818679","volume":"12","author":"DS Hong","year":"2022","unstructured":"Hong, D. S. et al. Phase 1 clinical trial evaluating the safety and anti-tumor activity of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors. Front. Oncol. 12, 818679 (2022).","journal-title":"Front. Oncol."},{"key":"3650_CR24","doi-asserted-by":"publisher","first-page":"e003581","DOI":"10.1136\/jitc-2021-003581","volume":"10","author":"GR Blumenschein","year":"2022","unstructured":"Blumenschein, G. R. et al. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer. J. Immunother. Cancer 10, e003581 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"3650_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"3650_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3650_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3650_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00000421-198708000-00017","volume":"10","author":"R Pazdur","year":"1987","unstructured":"Pazdur, R., Samson, M. K. & Baker, L. H. Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas. Am. J. Clin. Oncol. 10, 341\u2013343 (1987).","journal-title":"Am. J. Clin. Oncol."},{"key":"3650_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/00000421-198804000-00011","volume":"11","author":"DD Von Hoff","year":"1988","unstructured":"Von Hoff, D. D. et al. Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study. Am. J. Clin. Oncol. 11, 146\u2013148 (1988).","journal-title":"Am. J. Clin. Oncol."},{"key":"3650_CR30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/bmj.290.6472.889","volume":"290","author":"HE Lambert","year":"1985","unstructured":"Lambert, H. E. & Berry, R. J. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Br. Med J. (Clin. Res Ed.) 290, 889\u2013893 (1985).","journal-title":"Br. Med J. (Clin. Res Ed.)"},{"key":"3650_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0277-5379(87)90075-7","volume":"23","author":"VH Bramwell","year":"1987","unstructured":"Bramwell, V. H. et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur. J. Cancer Clin. Oncol. 23, 311\u2013321 (1987).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"3650_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cncr.22427","volume":"109","author":"HJ Gogas","year":"2007","unstructured":"Gogas, H. J., Kirkwood, J. M. & Sondak, V. K. Chemotherapy for metastatic melanoma: time for a change? Cancer 109, 455\u2013464 (2007).","journal-title":"Cancer"},{"key":"3650_CR33","doi-asserted-by":"publisher","first-page":"e008668","DOI":"10.1136\/jitc-2023-008668","volume":"12","author":"M Wermke","year":"2024","unstructured":"Wermke, M. et al. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J. Immunother. Cancer 12, e008668 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"3650_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3650_CR35","doi-asserted-by":"crossref","unstructured":"Lanitis, E., Dangaj, D., Irving, M. & Coukos, G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann. Oncol. 28, xii-18\u2013xii32 (2017).","DOI":"10.1093\/annonc\/mdx238"},{"key":"3650_CR36","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759\u20131776 (2021).","journal-title":"Br. J. Cancer"},{"key":"3650_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero, I., Rouzaut, A., Motz, G. T. & Coukos, G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 4, 522\u2013526 (2014).","journal-title":"Cancer Discov."},{"key":"3650_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","volume":"25","author":"TF Gajewski","year":"2013","unstructured":"Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268\u2013276 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"3650_CR39","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.21037\/tcr-20-2547","volume":"10","author":"X Xie","year":"2021","unstructured":"Xie, X., Li, X. & Yao, W. A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors. Transl. Cancer Res. 10, 1119\u20131130 (2021).","journal-title":"Transl. Cancer Res."},{"key":"3650_CR40","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","volume":"51","author":"V Heinemann","year":"2015","unstructured":"Heinemann, V. et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur. J. Cancer 51, 1927\u20131936 (2015).","journal-title":"Eur. J. Cancer"},{"key":"3650_CR41","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3650_CR42","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/JCO.19.01464","volume":"38","author":"A Betof Warner","year":"2020","unstructured":"Betof Warner, A. et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J. Clin. Oncol. 38, 1655\u20131663 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3650_CR43","doi-asserted-by":"publisher","first-page":"11562","DOI":"10.1200\/JCO.2022.40.16_suppl.11562","volume":"40","author":"SP D'Angelo","year":"2022","unstructured":"D'Angelo, S. P. et al. Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (\u2018afami-cel\u2019 [formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid\/round cell liposarcoma phase 1 and phase 2 trials. J. Clin. Oncol. 40, 11562 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3650_CR44","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney, J. et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer 10, e005755 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"3650_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3650_CR46","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 24, 4960\u20134967 (2018).","journal-title":"Clin. Cancer Res."},{"key":"3650_CR47","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"3650_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3650_CR49","doi-asserted-by":"crossref","unstructured":"Davar, D. et al. Phase I dose escalation of IMC-C103C, a CD3\u00d7MAGE-A4 T-cell receptor (TCR) bispecific protein. Ann. Oncol. 32, S1411\u2013S1413 (2021).","DOI":"10.1016\/j.annonc.2021.10.109"},{"key":"3650_CR50","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"3650_CR51","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Via","year":"2021","unstructured":"Da Via, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616\u2013619 (2021).","journal-title":"Nat. Med."},{"key":"3650_CR52","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger, S. et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 7, 1420\u20131435 (2017).","journal-title":"Cancer Discov."},{"key":"3650_CR53","doi-asserted-by":"crossref","unstructured":"Paschen, A., Melero, I. & Ribas, A. Central role of the antigen-presentation and interferon-\u03b3 pathways in resistance to immune checkpoint blockade. Annu. Rev. Cancer Biol. 6, 85\u2013102 (2022).","DOI":"10.1146\/annurev-cancerbio-070220-111016"},{"key":"3650_CR54","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"3650_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"3650_CR56","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.4049\/jimmunol.171.10.4974","volume":"171","author":"S Walter","year":"2003","unstructured":"Walter, S. et al. Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC\/anti-CD28-coated microspheres. J. Immunol. 171, 4974\u20134978 (2003).","journal-title":"J. Immunol."},{"key":"3650_CR57","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/nm.3358","volume":"19","author":"E Kobayashi","year":"2013","unstructured":"Kobayashi, E. et al. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat. Med. 19, 1542\u20131546 (2013).","journal-title":"Nat. Med."},{"key":"3650_CR58","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1110\/ps.8.11.2418","volume":"8","author":"BE Willcox","year":"1999","unstructured":"Willcox, B. E. et al. Production of soluble \u03b1\u03b2 T-cell receptor heterodimers suitable for biophysical analysis of ligand binding. Protein Sci. 8, 2418\u20132423 (1999).","journal-title":"Protein Sci."},{"key":"3650_CR59","doi-asserted-by":"publisher","first-page":"eabo6135","DOI":"10.1126\/scitranslmed.abo6135","volume":"14","author":"GB Kim","year":"2022","unstructured":"Kim, G. B. et al. Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy. Sci. Transl. Med. 14, eabo6135 (2022).","journal-title":"Sci. Transl. Med."},{"key":"3650_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"3650_CR61","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"3650_CR62","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"3650_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"3650_CR64","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field, M. G. et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin. Cancer Res. 22, 1234\u20131242 (2016).","journal-title":"Clin. Cancer Res."}],"updated-by":[{"DOI":"10.1038\/s41591-025-03731-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03650-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:12:26Z","timestamp":1757167946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03650-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3650"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03650-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03731-6","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03731-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W.: honoraria: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GWT, Janssen, Merck Novartis, Pfizer, Serono and Synlab; consulting or advisory role: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo Europe GmbH, Eli Lilly, ImCheck Therapeutics, Immatics, ISA Pharmaceuticals, Novartis, PharmaMar, Regeneron, Tacalyx and Zymeworks; research funding (to institution): Roche; travel, accommodations, expenses: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo Europe GmbH, GEMoaB, Immatics, Iovance Biotherapeutics, Janssen Oncology, Merck\/Senoro, Pfizer and Sanofi\/Aventis. D.M.A.: research funding: Adaptimmune, GlaxoSmithKline and Immatics. A.M.T.: consulting or advisory role: Avstera, BioEclipse Therapeutics, BrYet, Diaccurate, Macrogenics, Nex-I and Vincerx; research funding: BrYet (to institution), AbbVie, Agenus, Immatics, Macrogenics, Novocure Ltd., OBI Pharma, Orionis, Parker Institute for Cancer Immunotherapy, Tachyon, Tempus, Tvardi Therapeutics and Vividion Therapeutics. T.A.W.H.: honoraria: Amgen, Bristol Myers Squibb, GlaxoSmithKline and Jazz Pharmaceuticals; consulting or advisory role: AbbVie, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, Kite\/Gilead, Novartis, Otsuka, Pfizer, Pierre-Fabre and Sanofi; travel, accomodations, expenses: AbbVie, Amgen, Astellas, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Immatics, Janssen, Jazz Pharmaceuticals, Kite\/Gilead, Kyverna Therapeutics, Medac, Neovii, Sanofi and Sobi. A.A.J.: stock or other ownership: Avenge Bio; consulting or advisory role: Avenge Bio, Eisei, GLG, Guidepoint, Macrogenics, Sentinel Bio and Theolytics; research funding: AstraZeneca, Eli Lilly, Immatics, Immunon, Iovance, Macrogenics, Merck and Xencor; travel, accomodations, expenses: Striker. R.R.: consulting or advisory role: Allogene, Autolus, Gilead, Incyte, Orca Bio, Quell Biotherapeutics, Sana Biotechnology and TScan; research funding (all to institution): AbbVie, Atara Biotherapeutics, Bristol Myers Squibb, Cabaletta, CareDx, Genentech, Gilead, Immatics, Incyte, Johnson & Johnson, Precision Biosciences, Sanofi, Synthekine, Takeda, TCR2 and TScan; expert testimony: Bayer; travel, accommodations, expenses: Gilead and Johnson & Johnson. C.B.: consulting fees: AOK Germany, AstraZeneca, Bayer Healthcare, BioNTech, Lindis Biotech and Sanofi Aventis; payment or honoraria for lectures, presentations, speakers\u02bc bureaus, manuscript writing or educational events: med update, Merck Serono and Roche Pharma; data safety monitoring board or advisory board: German Society of Hematology and Oncology (DGHO), Hamburg Cancer Society (HKG), German Cancer Society (DKG), National Network of German Cancer Centers (CCC)\/German Cancer Aid (DKH) and Northern Germany Society of Internal Medicine (NWGIM). W.A.: consulting or advisory role: Janssen; research funding (received through institution): Affimed and BioNTech; travel, accommodation, expenses: BioNTech, Immatics and Janssen; honoraria: Astellas, AstraZeneca, GlaxoSmithKline and Janssen. H.-G.R.: stock or other ownership: CureVac, Immatics and ViferaXS; consulting or advisory role: Immatics; patents, royalities, other intellectual property: CureVac, Immatics and ViferaXS. P.B.: consulting or advisory role: BeiGene, Bristol Myers Squibb and Kite; research funding: Bristol Myers Squibb. J.J.L.: data safety and monitoring board: AbbVie, Agenus, Evaxion, Immutep and Shionogi; scientific advisory board (no stock): 7 Hills, Affivant, BioCytics, Bright Peak, Exo, Fstar, Inzen, RefleXion and Xilio; scientific advisory board (stock): Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Elipscience, Kanaph, NeoTx, Onc.AI, OncoNano, physIQ, Pyxis, Saros, Stipe and Tempest; consultancy with compensation: AbbVie, Agenus, Alnylam, AstraZeneca, Askgene, Atomwise, Bayer, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Geneos, Gilead, Glenmark, HotSpot, Kadmon, Ko Bio Labs, Krystal, KSQ, Janssen, Ikena, Inzen, Immatics, Immunocore, Incyte, Instil, IO Biotech, LegoChem, Lyvgen, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Replimmune, Ribon, Roivant, Servier, STINGthera, Storm, Sumoitomo, Synlogic, Synthekine and Teva; research support (all to institution): AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Hot Spot, Ikena, Immatics, Imugene, Incyte, Janux, Kadmon, KAHR, Macrogenics, Merck, Synlogic, Takeda, Trishula, Tizona, Tscan, Werewolf and Xencor; patents: US-11638728 (\u2018Microbiome biomarkers for anti-PD-1\/PD-L1 responsiveness: diagnostic, prognostic and therapeutic uses thereof\u2019). K.A., L.B., S.B., J.F., S.G., S.H., N.H., J.H., M.A.K., D.M., A.M.-M., R.M., M.L., H.S., O.S., C.W., C.R., H.S.-J., T.W. and C.M.B. were employees of Immatics Biotechnologies GmbH during the course of this work and may have securities from Immatics. M.B.H., M.K., D.K., A.M., K.P., A.S. and S.W. were employees of Immatics US, Inc. during the course of this work and may have securities from Immatics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}